Staphylococcus aureus–derived lipoteichoic acid induces temporary T-cell paralysis independent of Toll-like receptor 2

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 3, 2016, Pages 780-790.e6

  Kaesler, Susanne ^a,b   Skabytska, Yuliya ^a   Chen, Ko Ming ^a,f   Kempf, Wolfgang E ^a,b   Volz, Thomas ^a,b   Köberle, Martin ^a,b   Wölbing, Florian ^a,b   Hein, Ulrike ^a   Hartung, Thomas ^c,d   Kirschning, Carsten ^e   Röcken, Martin ^a   Biedermann, Tilo ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF KONSTANZ   (Germany)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f University Medical Center Düsseldorf   (Germany)

Author keywords

atopic dermatitis; cell cycle; Lipoteichoic acid; Staphylococcus aureus; temporary unresponsiveness; T cell

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; LIPOTEICHOIC ACID; TOLL LIKE RECEPTOR 2; ALLERGEN; CYTOKINE; LIPOPOLYSACCHARIDE; MYD88 PROTEIN, MOUSE; MYELOID DIFFERENTIATION FACTOR 88; OVALBUMIN; TEICHOIC ACID; TLR2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATOPIC DERMATITIS; CD4+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN FLORA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CONTACT DERMATITIS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE;

ALLERGENS; ANIMALS; CELL PROLIFERATION; CYTOKINES; DERMATITIS, ATOPIC; DERMATITIS, CONTACT; FLUORESCEIN-5-ISOTHIOCYANATE; LIPOPOLYSACCHARIDES; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; OVALBUMIN; STAPHYLOCOCCUS AUREUS; T-LYMPHOCYTES; TEICHOIC ACIDS; TOLL-LIKE RECEPTOR 2;

EID: 84959292296     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.11.043     Document Type: Article

References (58)

1. 1 Tian, T., Liu, L., Freyschmidt, E.J., Murphy, G.F., Kupper, T.S., Fuhlbrigge, R.C., Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus. J Invest Dermatol 129 (2009), 70–78.
2. 2 Bieber, T., Atopic dermatitis. N Engl J Med 358 (2008), 1483–1494.
3. 3 Kaesler, S., Volz, T., Skabytska, Y., Koberle, M., Hein, U., Chen, K.M., et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. J Allergy Clin Immunol 134 (2014), 92–99.
4. 4 Lipinski, S., Rosenstiel, P., Debug your bugs—how NLRs shape intestinal host-microbe interactions. Front Immunol, 4, 2013, 479.
5. 5 Kuo, I.H., Yoshida, T., De Benedetto, A., Beck, L.A., The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol 131 (2013), 266–278.
6. 6 Akdis, C.A., Akdis, M., Bieber, T., Bindslev-Jensen, C., Boguniewicz, M., Eigenmann, P., et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 118 (2006), 152–169.
7. 7 Boguniewicz, M., Eichenfield, L.F., Hultsch, T., Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 112:suppl (2003), S140–S150.
8. 8 Kapp, A., Papp, K., Bingham, A., Fölster-Holst, R., Ortonne, J.P., Potter, P.C., et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 110 (2002), 277–284.
9. 9 Mosli, M.H., Rivera-Nieves, J., Feagan, B.G., T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. Drugs 74 (2014), 297–311.
10. 10 Leung, D.Y., Bhan, A.K., Schneeberger, E.E., Geha, R.S., Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol 71 (1983), 47–56.
11. 11 Mihm, M.C. Jr., Soter, N.A., Dvorak, H.F., Austen, K.F., The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 67 (1976), 305–312.
12. 12 Hamid, Q., Boguniewicz, M., Leung, D.Y., Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94 (1994), 870–876.
13. 13 Fournier, B., Philpott, D.J., Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev 18 (2005), 521–540.
14. 14 Myles, I.A., Datta, S.K., Staphylococcus aureus: an introduction. Semin Immunopathol 34 (2012), 181–184.
15. 15 Broker, B.M., Holtfreter, S., Bekeredjian-Ding, I., Immune control of Staphylococcus aureus—regulation and counter-regulation of the adaptive immune response. Int J Med Microbiol 304 (2014), 204–214.
16. 16 Leung, D.Y., Bieber, T., Atopic dermatitis. Lancet 361 (2003), 151–160.
17. 17 Nakamura, Y., Oscherwitz, J., Cease, K.B., Chan, S.M., Munoz-Planillo, R., Hasegawa, M., et al. Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature 503 (2013), 397–401.
18. 18 Volz, T., Kaesler, S., Biedermann, T., Innate immune sensing 2.0—from linear activation pathways to fine tuned and regulated innate immune networks. Exp Dermatol 21 (2012), 61–69.
19. 19 Akira, S., Uematsu, S., Takeuchi, O., Pathogen recognition and innate immunity. Cell 124 (2006), 783–801.
20. 20 Biedermann, T., Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol 86 (2006), 99–109.
21. 21 Komai-Koma, M., Jones, L., Ogg, G.S., Xu, D., Liew, F.Y., TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 101 (2004), 3029–3034.
22. 22 Thoma-Uszynski, S., Kiertscher, S.M., Ochoa, M.T., Bouis, D.A., Norgard, M.V., Miyake, K., et al. Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J Immunol 165 (2000), 3804–3810.
23. 23 Volz, T., Nega, M., Buschmann, J., Kaesler, S., Guenova, E., Peschel, A., et al. Natural Staphylococcus aureus-derived peptidoglycan fragments activate NOD2 and act as potent costimulators of the innate immune system exclusively in the presence of TLR signals. FASEB J 24 (2010), 4089–4102.
24. 24 Travers, J.B., Kozman, A., Mousdicas, N., Saha, C., Landis, M., Al-Hassani, M., et al. Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid. J Allergy Clin Immunol 125 (2010), 146–152 e1-2.
25. 25 Jin, H., He, R., Oyoshi, M., Geha, R.S., Animal models of atopic dermatitis. J Invest Dermatol 129 (2009), 31–40.
26. 26 Volz, T., Skabytska, Y., Guenova, E., Chen, K.M., Frick, J.S., Kirschning, C.J., et al. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol 134 (2014), 96–104.
27. 27 Skabytska, Y., Wölbing, F., Günther, C., Köberle, M., Kaesler, S., Chen, K.M., et al. Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity 41 (2014), 762–775.
28. 28 Ginsburg, I., Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2 (2002), 171–179.
29. 29 Cleveland, M.G., Gorham, J.D., Murphy, T.L., Tuomanen, E., Murphy, K.M., Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect Immun 64 (1996), 1906–1912.
30. 30 Standiford, T.J., Arenberg, D.A., Danforth, J.M., Kunkel, S.L., VanOtteren, G.M., Strieter, R.M., Lipoteichoic acid induces secretion of interleukin-8 from human blood monocytes: a cellular and molecular analysis. Infect Immun 62 (1994), 119–125.
31. 31 von Aulock, S., Morath, S., Hareng, L., Knapp, S., van Kessel, K.P., van Strijp, J.A., et al. Lipoteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology 208 (2003), 413–422.
32. 32 Okusawa, T., Fujita, M., Nakamura, J., Into, T., Yasuda, M., Yoshimura, A., et al. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun 72 (2004), 1657–1665.
33. 33 Cardona, I.D., Cho, S.H., Leung, D.Y., Role of bacterial superantigens in atopic dermatitis: implications for future therapeutic strategies. Am J Clin Dermatol 7 (2006), 273–279.
34. 34 Kehrl, J.H., Wakefield, L.M., Roberts, A.B., Jakowlew, S., Alvarez-Mon, M., Derynck, R., et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163 (1986), 1037–1050.
35. 35 Datto, M.B., Li, Y., Panus, J.F., Howe, D.J., Xiong, Y., Wang, X.F., Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 92 (1995), 5545–5549.
36. 36 Hannon, G.J., Beach, D., p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371 (1994), 257–261.
37. 37 Polyak, K., Kato, J.Y., Solomon, M.J., Sherr, C.J., Massague, J., Roberts, J.M., et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8 (1994), 9–22.
38. 38 Dziarski, R., Platt, K.A., Gelius, E., Steiner, H., Gupta, D., Defect in neutrophil killing and increased susceptibility to infection with nonpathogenic gram-positive bacteria in peptidoglycan recognition protein-S (PGRP-S)-deficient mice. Blood 102 (2003), 689–697.
39. 39 Hoetzenecker, W., Echtenacher, B., Guenova, E., Hoetzenecker, K., Woelbing, F., Bruck, J., et al. ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression. Nat Med 18 (2011), 128–134.
40. 40 Kusunoki, T., Hailman, E., Juan, T.S., Lichenstein, H.S., Wright, S.D., Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J Exp Med 182 (1995), 1673–1682.
41. 41 Medzhitov, R., Recognition of microorganisms and activation of the immune response. Nature 449 (2007), 819–826.
42. 42 Morath, S., Stadelmaier, A., Geyer, A., Schmidt, R.R., Hartung, T., Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J Exp Med 195 (2002), 1635–1640.
43. 43 Massey, R.C., Horsburgh, M.J., Lina, G., Hook, M., Recker, M., The evolution and maintenance of virulence in Staphylococcus aureus: a role for host-to-host transmission?. Nat Rev Microbiol 4 (2006), 953–958.
44. 44 Lowy, F.D., How Staphylococcus aureus adapts to its host. N Engl J Med 364 (2011), 1987–1990.
45. 45 Foster, T.J., Immune evasion by staphylococci. Nat Rev Microbiol 3 (2005), 948–958.
46. 46 Kaesler, S., Sobiesiak, M., Kneilling, M., Volz, T., Kempf, W.E., Lang, P.A., et al. Effective T-cell recall responses require the taurine transporter Taut. Eur J Immunol 42 (2012), 831–841.
47. 47 Rooijakkers, S.H., Ruyken, M., van Roon, J., van Kessel, K.P., van Strijp, J.A., van Wamel, W.J., Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell Microbiol 8 (2006), 1282–1293.
48. 48 Edds, E.M., Bergamini, T.M., Brittian, K.R., Bacterial components inhibit fibroblast proliferation in vitro. ASAIO J 46 (2000), 33–37.
49. 49 Sheu, J.R., Lee, C.R., Lin, C.H., Hsiao, G., Ko, W.C., Chen, Y.C., et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. Thromb Haemost 83 (2000), 777–784.
50. 50 Lai, Y., Di Nardo, A., Nakatsuji, T., Leichtle, A., Yang, Y., Cogen, A.L., et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 15 (2009), 1377–1382.
51. 51 Lai, Y., Cogen, A.L., Radek, K.A., Park, H.J., Macleod, D.T., Leichtle, A., et al. Activation of TLR2 by a small molecule produced by Staphylococcus epidermidis increases antimicrobial defense against bacterial skin infections. J Invest Dermatol 130 (2010), 2211–2221.
52. 52 Reynolds, J.M., Pappu, B.P., Peng, J., Martinez, G.J., Zhang, Y., Chung, Y., et al. Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 32 (2010), 692–702.
53. 53 Round, J.L., Lee, S.M., Li, J., Tran, G., Jabri, B., Chatila, T.A., et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332 (2011), 974–977.
54. 54 Grice, E.A., Kong, H.H., Conlan, S., Deming, C.B., Davis, J., Young, A.C., et al. Topographical and temporal diversity of the human skin microbiome. Science 324 (2009), 1190–1192.
55. 55 Kong, H.H., Segre, J.A., Skin microbiome: looking back to move forward. J Invest Dermatol 132 (2012), 933–939.
56. 56 Round, J.L., Mazmanian, S.K., Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107 (2010), 12204–12209.
57. 57 Geuking, M.B., Cahenzli, J., Lawson, M.A., Ng, D.C., Slack, E., Hapfelmeier, S., et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 34 (2011), 794–806.
58. 58 Kong, H.H., Oh, J., Deming, C., Conlan, S., Grice, E.A., Beatson, M.A., et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 22 (2012), 850–859.